ACC 2025: Imbria’s ninerafaxstat data shows potential for cardiometabolic HFpEF
Based on the Phase II data, Imbria Pharmaceuticals’ inerafaxstat could complement existing treatments rather than replace ...
Scientists discover new inhibitors of inflammation-related enzyme
Using computational tools and virtual screening, researchers at the Center for Redox Processes in Biomedicine (Redoxoma) have ...
Yahoo Finance21d
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
the Company’s second fatty acid synthase (FASN) inhibitor. TVB-3567 is a potent and selective small molecule FASN inhibitor, planned to enter clinical development for the treatment of acne.
Business Insider21d
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet ...